Analysis of influencing factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium in patients with chronic renal insufficiency
10.3760/cma.j.cn114015-20231222-00927
- VernacularTitle:头孢哌酮钠舒巴坦钠致慢性肾功能不全患者凝血功能异常的影响因素分析
- Author:
Yuanmei YAN
1
;
Yuexin ZHENG
;
Lusi MAI
;
Huili CHANG
Author Information
1. 广州医科大学附属清远医院（清远市人民医院）药学部，清远 511518
- Publication Type:Journal Article
- Keywords:
Renal insufficiency, chronic;
Cefoperazone;
Sulbactam;
Blood coagulation disorders;
Risk factors
- From:
Adverse Drug Reactions Journal
2024;26(5):280-284
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the influencing factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium in patients with chronic renal insufficiency.Methods:The medical records of adult patients with chronic renal insufficiency, who were hospitalized and treated with cefoperazone sodium and sulbactam sodium in the Department of Nephrology of the Affiliated Qingyuan Hospital, Guangzhou Medical University, Qingyuan People′s Hospital from January 2021 to December 2022, were collected. Patients who developed coagulation disorders related to cefoperazone sodium and sulbactam sodium were imputed as having an end-point event, and the occurrence of end-point events in these patients was analyzed descriptively. According to whether an end-point event occurred, patients were divided into end-point event group and non-end point event group. Univariate and multivariate logistic regression analysis were performed on the risk of end-point events.Results:A total of 121 patients with renal insufficiency were included in the analysis, including 76 males (62.8%) and 45 females (37.2%), aged (66±13) years. Among 121 patients, 39 (32.2%) had end-point events, and 6 (5.0%) had clinical bleeding. The results of univariate analysis showed that the differences in age, renal replacement therapy, and daily and total doses of cefoperazone sodium and sulbactam sodium of patients between 2 groups were statistically significant (all P<0.05). Multivariate logistic regression analysis was performed using the occurrence of end-point events as dependent variables, and age, renal replacement therapy, and daily and total doses of cefoperazone sodium and sulbactam sodium as independent variables. The results showed that only older age was an independent risk factor for the occurrence of end-point events (odds ratio=1.044, 95% confidence interval: 1.004-1.086, P=0.029). Conclusions:Patients with renal insufficiency have a higher risk of coagulation disorders in treatment with cefoperazone sodium and sulbactam sodium, and older age is an independent risk factor. Cefoperazone sodium and sulbactam sodium should be used cautiously in elder patients, and coagulation function monitoring should be strengthened in clinical use.
